Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NN1250 vs Insulin Glargine in Type 2 Diabetes (BEGIN: LOW VOLUME)
NCT01068665Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2010
- Primary completion
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Mar 2010; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01068665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01068665.